Communications Biology (Nov 2022)
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma
- Mehran Makvandi,
- Minu Samanta,
- Paul Martorano,
- Hwan Lee,
- Sarah B. Gitto,
- Khushbu Patel,
- David Groff,
- Jennifer Pogoriler,
- Daniel Martinez,
- Aladdin Riad,
- Hannah Dabagian,
- Michael Zaleski,
- Tara Taghvaee,
- Kuiying Xu,
- Ji Youn Lee,
- Catherine Hou,
- Alvin Farrel,
- Vandana Batra,
- Sean D. Carlin,
- Daniel J. Powell,
- Robert H. Mach,
- Daniel A. Pryma,
- John M. Maris
Affiliations
- Mehran Makvandi
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Minu Samanta
- Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
- Paul Martorano
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Hwan Lee
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Sarah B. Gitto
- Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania
- Khushbu Patel
- Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
- David Groff
- Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
- Jennifer Pogoriler
- Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia
- Daniel Martinez
- Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia
- Aladdin Riad
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Hannah Dabagian
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Michael Zaleski
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Tara Taghvaee
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Kuiying Xu
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Ji Youn Lee
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Catherine Hou
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Alvin Farrel
- Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
- Vandana Batra
- Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
- Sean D. Carlin
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Daniel J. Powell
- Ovarian Cancer Research Center, Division of Gynecology Oncology, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania
- Robert H. Mach
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- Daniel A. Pryma
- Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania Perelman School of Medicine
- John M. Maris
- Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia
- DOI
- https://doi.org/10.1038/s42003-022-04209-8
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 9
Abstract
The efficacy and toxicity of the PARP inhibitor parthanatine, radiolabeled with the alpha particle emitter astatine-211, in 11 patient derived neuroblastoma murine xenografts is investigated.
